Pharma Raises Concerns About Draft EU GDP Guideline
This article was originally published in The Gold Sheet
Executive Summary
The European Commission needs to fine tune its good distribution practices (GDP) guideline, the pharmaceutical industry said in comments on a proposed draft revision. Key issues include segregating EU and non-EU product, transportation vs. storage conditions, applicability to investigational products and time limits for transportation hubs.
You may also be interested in...
Regulatory Authorities Worldwide are Scrutinizing GDPs During Inspections
Regulators worldwide are increasingly scrutinizing pharmaceutical manufacturers’ good distribution practices during GMP inspections as GDP regulations continue to proliferate, says an industry representative who discusses how to comply with different regulations.
Regulatory Authorities Worldwide are Scrutinizing GDPs During Inspections
Regulators worldwide are increasingly scrutinizing pharmaceutical manufacturers’ good distribution practices (GDPs) during GMP inspections as GDP regulations continue to proliferate, says an industry representative who discusses how to comply with different regulations and notes some of the challenges in instituting robust GDPs. USP is the latest player in the increasingly crowded GDP arena.
The Anti-Falsification Directive: Europe’s Answer to Global Supply Chain Threats
The European Union July 1 published its directive on falsified medicines, setting into motion a tightening of Europe’s pharmaceutical supply chain that will for the most part take place over the next 18 months – and that could cost pharmaceutical companies billions of Euros.